FIELD: medicine.
SUBSTANCE: invention refers to medicine and concerns an osmotic delivery system promoting Exenatid release at a constant speed varying within approximately 5 mcg/day to approximately 160 mcg/day. The present invention also concerns a method of treating Insulin-independent diabetes in a subject and a method of treating obesity in a subject.
EFFECT: invention provides improved therapeutic consistency, higher clinical effectiveness, improved quality of life for the subjects recovered (in comparison with the injection therapy), and enabled immediate treatment interruption by removing the osmotic delivery system.
15 cl, 5 ex, 5 dwg, 5 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| RAPID ACCOMPLISHMENT AND/OR TERMINATION OF SUBSTANTIAL STABLE DRUG DELIVERY | 2010 |
|
RU2753280C2 |
| FAST ACHIEVEMENT AND/OR COMPLETION OF SUBSTANTIAL STABLE DRUG DELIVERY | 2010 |
|
RU2547990C2 |
| FAST ACHIEVEMENT AND/OR TERMINATION OF SIGNIFICANT STABLE DRUG DELIVERY | 2014 |
|
RU2703471C2 |
| POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
| METHOD FOR PREVENTING GLP-1 SIDE EFFECTS | 2008 |
|
RU2474415C2 |
| METHODS FOR DELIVERY OF NEUROPROTECTIVE POLYPEPTIDE TO CENTRAL NERVOUS SYSTEM | 2017 |
|
RU2790566C2 |
| ACTIVE SUBSTANCE DELIVERY | 2008 |
|
RU2467741C2 |
| INSULINOTROPIC PEPTIDE DERIVATIVE WITH MODIFIED N-TERMINAL CHARGE | 2014 |
|
RU2673179C2 |
| EXENATID ANALOGUES | 2010 |
|
RU2422461C1 |
| USE OF LONG-ACTING GLP-1 PEPTIDES | 2013 |
|
RU2657573C2 |
